Other immune check point molecules (sometimes considered stimulatory) such as CD27, CD38, CD47, CD137 and CD278 (Fig. ) exhibited similar degree of co-occurrences with emerging solid tumors. Immune checkpoint molecules (both inhibitory and others/stimulatory) show no particular preferences for liquid tumors except for CD38 with multiple myeloma (MM) and acute myeloid leukemia (AML) (Supplementary Fig. ). • Unsurprisingly, ADCs show the greatest overlap with breast cancer (Fig . ) and this can be attributed to the development and approval of ado -trastuzumab emtansine (T-DM1/Kadcyla), trastuzumab deruxtecan (T-DXd/Enhertu), and sacituzumab govetican (SG/Trodelvy) for the treatment of breast cancer. This is followed closely by cooccurrences of ADCs with lung cancer indicating increased traction. Trastuzumab Deruxtecan (DS-8201a, T-DXd) became the first ADC to gain US FDA approval for the treatment of lung cancer in 2022. • Cancer vaccines correlate more with liver, lung, breast, and colon cancer as compared to other types of cancer. • Kinase inhibitors correlate with lung, liver, and breast cancer over most of the other types (Fig. ). • CARs show the highest co-occurrence with ovarian cancer. While originally most effective against hematological malignancies, in recent years there has been increasing push towards use of CAR-T for solid tumors with a lot of research focused around ovarian cancer perhaps accounting for this trend. 76,77 • TLR agonists, BCL2 inhibitors, and STING agonists display similar degree s of cooccurrences with various types of solid tumors. • Pharmaceutical nanoparticles, often utilized to deliver anti-cancer drugs, appear to show a slightly higher degree of overlap with breast cancer as compared to the rest. • Therapies such as photodynamic, photothermal, sonodynamic, and chemodynamic appear to show no particular preference for types of cancer. • In terms of liquid tumors, almost all the selected therapies show equal co-occurrences with the 4 types of emerging liquid tumors except for cancer vaccine which appears to show a slight preference for AML and MM as compared to acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) and kinase inhibitors for ALL and AML (Supplementary Fig. ).